Merck CEO Invests $1B to Boost Production of Top-Selling Cancer Drug Keytruda

Robert Davis' strategic move aims to meet growing global demand for the groundbreaking immunotherapy treatment.

Apr. 13, 2026 at 2:19am

Got story updates? Submit your updates here. ›

A minimalist design in the style of Keith Haring where a human immune cell is defined entirely by glowing, vibrant neon lines against a deep, dark background, emphasizing the shape and electrical energy of the cell's function.Merck's Keytruda immunotherapy drug harnesses the power of the human immune system to fight cancer, transforming treatment for countless patients.Wilmington Today

Merck CEO Robert Davis has announced a $1 billion investment to expand the company's biologics center in Wilmington, Delaware, with the goal of making it the primary global production hub for the cancer immunotherapy drug Keytruda. Keytruda has become a beacon of hope for countless cancer patients by unleashing the full potential of the immune system against cancer, and doctors are now combining it with other treatments to achieve even greater results. However, the focus on a single drug has sparked debate about healthcare priorities and balancing innovation with accessibility.

Why it matters

Keytruda has transformed the lives of patients with various cancers, but the growing demand for the life-saving medication has raised questions about the ethics of Merck's strategy to focus primarily on one treatment when there are countless other diseases and conditions in need of attention.

The details

Keytruda, an immunotherapy drug developed by Merck, has become the world's top-selling drug due to its ability to remove the brakes that normally hold immune cells back from attacking cancerous cells. Doctors are now combining Keytruda with other cancer treatments to achieve even greater results. To meet the rising global demand for Keytruda, Merck CEO Robert Davis has announced a $1 billion investment to expand the company's biologics center in Wilmington, Delaware, with the goal of making it the primary production hub for the drug worldwide.

  • Merck announced the $1 billion investment in April 2026.

The players

Robert Davis

The CEO of Merck, the pharmaceutical company responsible for the production and distribution of the groundbreaking cancer immunotherapy drug Keytruda.

Merck

A leading pharmaceutical company that developed the cancer immunotherapy drug Keytruda, which has become the world's top-selling drug.

Got photos? Submit your photos here. ›

What’s next

Merck's $1 billion investment in the Wilmington, Delaware biologics center is expected to significantly increase the global production capacity for Keytruda, helping to meet the growing demand for the cancer immunotherapy drug.

The takeaway

Merck's strategic focus on Keytruda has made it the world's top-selling drug, but it has also sparked debate about healthcare priorities and the balance between innovation and accessibility. As the demand for Keytruda continues to rise, Merck's $1 billion investment in expanding production capacity aims to ensure more cancer patients can access this life-saving treatment, though some may argue the company should diversify its efforts to address a broader range of medical needs.